ICYMI: INO-3107 for RRP Earns EC Orphan Drug Designation
Photo by Robina Weermeijer on Unsplash

ICYMI: INO-3107 for RRP Earns EC Orphan Drug Designation

  In May 2023, Pharmaceutical Technology reported that INO-3107, a DNA medicine vaccine candidate developed by biotechnology company Inovio Pharmaceuticals (“Inovio”), received Orphan Drug designation from the European Commission. INO-3107…

Continue Reading ICYMI: INO-3107 for RRP Earns EC Orphan Drug Designation
Positive Interim Data Available: INO-3107 for Recurrent Respiratory Papillomatosis
illustrade / Pixabay

Positive Interim Data Available: INO-3107 for Recurrent Respiratory Papillomatosis

  In an October 13, 2022 news release from biotechnology company INOVIO, the company shared that positive interim data was available from a Phase 1/2 study. Within the study, researchers…

Continue Reading Positive Interim Data Available: INO-3107 for Recurrent Respiratory Papillomatosis
ICYMI: Recurrent Respiratory Papillomatosis Treatment Receives Orphan Drug Designation
source: pixabay.com

ICYMI: Recurrent Respiratory Papillomatosis Treatment Receives Orphan Drug Designation

INO-3107, a treatment for recurrent respiratory papillomatosis (RRP), has recently received the Orphan Drug Designation from the FDA. This treatment is currently being evaluate in a Phase 1/2 trial by…

Continue Reading ICYMI: Recurrent Respiratory Papillomatosis Treatment Receives Orphan Drug Designation
Experimental Treatment for Recurrent Respiratory Papillomatosis Earns Orphan Drug Designation
source: pixabay.com

Experimental Treatment for Recurrent Respiratory Papillomatosis Earns Orphan Drug Designation

According to a story from PR Newswire, the biotechnology company INOVIO has just announced that the company's investigational product candidate INO-3107 has earned Orphan Drug designation from the US Food…

Continue Reading Experimental Treatment for Recurrent Respiratory Papillomatosis Earns Orphan Drug Designation